NCT00496301View on ClinicalTrials.gov

Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

December 31, 2008

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Gemcitabine, Capecitabine and Sorafenib (6 cycles)

Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21

Trial Locations (10)

15706

Hospital Santiago de Compostela, A Coruña

17007

Hospital Josep Trueta, Girona

21005

Hospital Juan Ramón Jiménez, Huelva

29010

Hospital Clínico Virgen de la Victoria, Málaga

31008

Clínica Universitaria de Navarra, Pamplona

36204

Hospital Xeral Cies, Vigo

41009

Hospital Virgen Macarena, Seville

48013

Hospital de Basurto, Bilbao

08003

Hospital del Mar, Barcelona

08035

Hospital Vall d´Hebron, Barcelona

All Listed Sponsors
lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT00496301 - Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC | Biotech Hunter | Biotech Hunter